A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study

Trial Profile

A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Oct 2015 Planned End Date changed from 1 Jun 2015 to 1 Aug 2019 as per ClinicalTrials.gov record.
    • 19 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top